Abstract: The disclosure herein relates to a flow path comprising half clamps 1 having an interior surface surrounding a flexible tubing 3 connection with a barb adapter 3, when assembled may be placed within a clamshell reduce or prevent deformation of the flexible tubing.

Abstract: [Problem] To provide a semiconductor aqueous composition capable of preventing a pattern collapse and suppressing a bridge defect. [Means for Solution] A semiconductor aqueous composition comprising a single or plurality of surfactant(s) having a monovalent anion part represented by formula (I): Chain 1-X1—X2-Chain 2 (I) wherein, X1 and X2 are each independently —C(=0)- or —S(=0)2-, and Chain 1 and Chain 2 are each independently a linear or branched C1-20 alkyl, wherein one or more H in said C1-20 alkyl are replaced by F, and one or more methylenes in Chain 1 may be replaced by -0-, with the proviso that Chain 1 and Chain 2 may be bonded to form a ring structure) and a monovalent cation part other than hydrogen ion; and water.

Abstract: A solid form of [(1R)-2-(1-benzofuran-3-yl)-1-{[(1S,2R,4R)-7-oxabicyclo[2.2.1]heptan-2-yl]formamido}ethyl]boronic acid, hydrates, solvates, and/or adducts thereof can be used as LMP7 inhibitors. The solid form can be a trimeric crystalline anhydrous form characterized by two or more 2? XRPD peaks at 6.5±0.2°, 11.2±0.2°, 17.1±0.2°, 19.6±0.2°, and 21.9±0.2° degrees.

Abstract: VHH-based NKp30 binders are provided having favorable characteristics. Moreover, pharmaceutical compositions including such a compound are produced and methods of medical treatment with such compounds and pharmaceutical compositions are developed. In a compound including a VHH antibody domain or fragment thereof, the VHH antibody domain or fragment thereof can have complementary determining regions CDR1, CDR2, and CDR3 of one of VHH1 to VHH16, or a humanized modification thereof, or a modification involving replacement, addition, and/or deletion of up to three amino acids in each complementary determining region.

Abstract: The present application relates to compounds of formula (I) containing a group selected from amino groups, bridged amino groups and carbazole groups, to processes for preparation thereof, and to the use thereof in electronic devices, and in particular OLEDs.

Abstract: The present invention relates to a display device, in particular a backlit display device having a visible side and a back side, which appears opaque in colour and texture on viewing of the visible side without backlighting, but, with the backlighting switched on, is sufficiently transparent that the transmission of information by the light source from the back side is possible, and to the production of a display device of this type and to the use thereof.

Abstract: cMET inhibitors can be used in the treatment of glioblastoma, including disseminated glioblastoma harboring MET amplification.

Abstract: The disclosed technology relates to a continuous impregnating process of active pharmaceutical ingredients (API) onto porous carriers, a continuous impregnation process for making impregnated porous carrier particles and pharmaceutical dosage forms comprising impregnated porous carrier particles, impregnated porous carrier particles and pharmaceutical dosage forms comprising impregnated porous carrier particles prepared by the continuous impregnation process.

Abstract: Reactive mesogens (RMs) derived from tolane, mixtures and formulations comprising them, polymers obtained from such RMs and RM mixtures, and the use of the RMs, RM mixtures and polymers in optical or electrooptical components or devices.

Abstract: [Problem] To obtain a substrate cleaning solution capable of cleaning a substrate and removing particles. [Means for Solution] The present invention is a substrate cleaning solution comprising an insoluble or hardly soluble solute (A), a soluble solute (B), and a solvent (C).

Abstract: The invention relates to polymers having at least one repeating unit of the following formula (I): wherein Ar1, Ar2, Ar3 and Ar4, R and X, and a, b, c, d, e and f can have the meanings defined in claim 1, to processes for the preparation thereof and to the use thereof in electronic or optoelectronic devices, in particular in organic electroluminescent devices, so-called OLEDs (OLED?Organic Light Emitting Diodes). The present invention also relates to electronic or optoelectronic devices, in particular organic electroluminescent devices, which contain said polymers.

Abstract: The present invention describes amines with dibenzofuran, dibenzothiophene and fluorene groups, especially for use as triplet matrix materials in organic electroluminescent devices. The invention further relates to a process for preparing the compounds of the invention and to electronic devices comprising these.

Abstract: Tricyclic heterocycles are useful as TEAD binders and/or inhibitors of YAP-TEAD. Tricyclic heterocycles can be used for TAZ-TEAD protein-protein interaction or binding and for the prevention and/or treatment of several medical conditions including hyperproliferative disorders and diseases, in particular cancer.

Abstract: A liquid crystal medium comprising a) one or more compounds of formula I and one or more compounds of the formula T and one or more compounds of the formula S1 and an electronic component comprising said LC medium, operable in the visible (VIS), infrared (IR) or microwave region of the electromagnetic spectrum. Also, the use of said LC medium in the IR, VIS or microwave region and to devices comprising said electronic component.

Abstract: The present invention relates to compounds and pharmaceutically acceptable salts or solvates thereof for use in the treatment or prevention of fascioliasis. Some of these compounds are novel per se and also have activity as inhibitors of Schistosoma growth. The invention also relates to pharmaceutical compositions comprising such novel compounds, salts or solvates and to the use of such novel compounds as medicaments, in particular in the treatment or prevention of schistosomiasis, also known as bilharzia.

Abstract: The present invention provides a method for producing a novel amorphous silicon sacrifice film and an amorphous silicon forming composition capable of filling trenches having a high aspect ratio to form an amorphous silicon sacrifice film that is excellent in affinity with a substrate. A method for producing an amorphous silicon sacrifice film, comprising (i) polymerizing a cyclic polysilane comprising 5 or more silicon or a composition comprising the cyclic polysilane by light irradiation and/or heating to form a polymer having a polysilane skeleton, (ii) applying an amorphous silicon forming composition comprising said polymer having a polysilane skeleton, polysilazane and a solvent above a substrate to form a coating film, and (iii) heating the coating film in a non-oxidizing atmosphere.

Abstract: The present invention relates to a method for forming an organic element of an electronic device having at least two different pixel types including a first pixel type (pixel A) and a second pixel type (pixel B), —wherein at least one layer of pixel A is deposited by applying an ink A containing at least one organic functional material A and at least one solvent A by a printing process, —wherein at least one layer of pixel B is deposited by applying an ink B containing at least one organic functional material B and at least one solvent B by a printing process, —wherein at least one organic functional material A and at least one organic functional material B are different, and —wherein at least one solvent A and at least one solvent B are different, characterized in that both inks, ink A and ink B, in addition contain at least one common solvent S, and characterized in that the boiling point of solvent A and the boiling point of solvent B is at least 10° C. lower than the boiling point of the common solvent S.

Abstract: A method can treat a patient suffering from at least one of fibrosis and a fibrotic disorder. The method includes administering a therapeutically effective amount of an anti-?v integrin antibody DI17E6, or a biologically active variant or modification thereof, to the patient.

Abstract: The present invention relates to a new class of dielectric polymer material, which is particularly suitable for the manufacturing of electronic devices. The dielectric polymer material is formed by reacting bismaleimide compounds and shows an advantageous well-balanced profile of favorable material properties. The bismaleimide compounds have an oligomeric structure with an oligoamide extended repeating unit in the middle part of the molecule and maleimide groups at each terminal end of the molecule. There is further provided a method for forming said dielectric polymer material. Beyond that, the present invention relates to the dielectric polymer material and to an electronic device comprising the same.

Abstract: A method for controlling the state of two or more liquid crystal-based switchable windows includes in a first step providing correction data which define a relationship between a state signal and an output voltage level. The correction data is provided for each of the switchable windows and the state of the switchable windows may be adjusted according to the state signal between a minimum and maximum level. In a subsequent step, the state signal is provided which defines the desired state of one or more selected switchable windows. In a further step, a required voltage level is determined for setting the desired state based on the state signal and the respective correction data for each of the one or more selected windows. In a subsequent step d), an AC output voltage is generated having the required voltage level for each of the one or more selected windows.